Overview

* Structure Therapeutics ( GPCR ) Q2 net loss widens to $61.7 mln from $26.0 mln yr ago

* Company holds $786.5 mln in cash, funding operations through 2027

* ACCESS and ACCESS II studies on track for year-end 2025 data readouts

Outlook

* Company anticipates cash position of $786.5 mln to fund operations through at least 2027

*

Result Drivers

* R&D EXPENSES - Increase in R&D expenses due to clinical trial costs and personnel expansion for GLP-1R franchise

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$61.66

Income mln

Q2 -$70.45

Income mln

From

Operatio

ns

Q2 $70.45

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Structure Therapeutics Inc ( GPCR ) is $75.00, about 77.8% above its August 5 closing price of $16.68

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)